Preliminary Phase 1 Study Results Show Strong Anti-Tumor Activity and Favorable Safety Profile for First-in-Class Small Molecule MYB mRNA ...
A new editorial paper was published in Oncoscience (Volume 10) on June 28, 2023, entitled, "Adenoid cystic carcinoma of the head and neck – treatment strategies of a highly malignant tumor with ...
SALT LAKE CITY, Feb. 8, 2021 /PRNewswire/ — Elevar Therapeutics, Inc. ("Elevar"), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for ...
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes Eligible patients had R/M ACC with progression within 6 months before enrollment. Treatment ...
Down-regulation of target gene expression in human white blood cells (hWBCs) by MRX34, a liposomal miR-34 mimic: Next generation sequencing (NGS) results from a first-in-human trial of microRNA cancer ...
- REM-422 granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of ACC and AML - Advances REM-422, an oral small molecule messenger RNA (mRNA) degrader to ...
A new paper published by researchers at Fox Chase Cancer Center highlights the case of a patient who was diagnosed with adenoid cystic carcinoma (ACC) after a molecular panel identified the presence ...
“Proton therapy [...] seems to have decisive advantages with regard to the long-term survival of [adenoid cystic carcinoma] [...]” In general, tumors originating from the minor salivary glands often ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results